Novo Nordisk A/S (NVO)
91.29
-3.44
(-3.63%)
USD |
NYSE |
Sep 21, 16:00
92.16
+0.87
(+0.95%)
Pre-Market: 08:40
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 408.38B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 85.17% |
Valuation | |
PE Ratio | 43.33 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 14.52 |
Price to Book Value | 30.93 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 0.2209 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.2841 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 25.29% |
Profile
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
URL | https://www.novonordisk.com |
Investor Relations URL | https://www.novonordisk.com/investors.html |
HQ State/Province | N/A |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Large Cap/Growth |
Next Earnings Release | Nov. 02, 2023 |
Last Earnings Release | Aug. 10, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Aug. 18, 2023 |
Ratings
Profile
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
URL | https://www.novonordisk.com |
Investor Relations URL | https://www.novonordisk.com/investors.html |
HQ State/Province | N/A |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Large Cap/Growth |
Next Earnings Release | Nov. 02, 2023 |
Last Earnings Release | Aug. 10, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Aug. 18, 2023 |